Zanko VL, Domislovic V, Trkulja V, et al. - Among adults suffering from non‐alcoholic fatty liver disease (NAFLD), this randomized (2:1), double‐blind, single‐centre, 12‐month trial was undertaken to determine how vitamin D could impact transient elastography (TE, FibroScan) indices of liver steatosis (controlled attenuation parameter) and fibrosis (liver stiffness measurement). Vitamin D (1000 IU/day) (n = 201) or a matching placebo (n = 110) was administered to patients with NAFLD. Findings demonstrated that, in patients with NAFLD, reduced TE indices of liver steatosis and fibrosis in relation to low‐medium dose supplementation of vitamin D (1000 IU/day) over 12 months. Serum uric acid, gamma‐glutamyltransferase, and fasting serum insulin levels as well as the homeostatic model assessment of insulin resistance index were reduced with vitamin D.